Skip to content

Detecting Low-Abundant Neurofilament Light Chain

Available On-Demand

Speaker

Rick Wiese

Rick Wiese, Ph.D.

Head of Singleplex & Special Protein Platforms R&D
Merck KGaA, Darmstadt, Germany

Rick Wiese holds a PhD from FDA NCTR and has over 22 years of experience in immunoassay development and production. In 2007, he became R&D Manager for the MILLIPLEX® assay group and then moved to Operations as Senior Manager, Upstream Operations in 2013, working extensively on product and process engineering projects for immunoassay products. In 2021, Rick moved back to R&D as Head of Singleplex & Special Protein Platforms R&D.

Speaker Bio

Ultrasensitive assay technologies have enabled the measurement of low-abundant blood-based biomarkers of neurodegenerative diseases. They reduce the need for invasive CSF sample collection, streamline sample acquisition and screening, and empower the study of the transitions from health to disease.

Neurofilament light chain (NF-L) is a valuable biomarker for assessing the progression and treatment of Alzheimer’s Disease, Multiple Sclerosis, and Huntington’s Disease and is under investigation as a potential biomarker for several other neurological disorders.

Join this webinar to learn how ultrasensitive Single Molecule Counting (SMC®️) technology enables measurements of a low-abundant blood-based neurodegeneration biomarker.

You’ll discover how the assay helps researchers investigate neurodegenerative conditions and neurological injury with consistent and reliable measurement of NF-L at sub-pg/mL concentrations in human blood and CSF samples.

In this webinar, you will learn about:

  • Why NF-L is emerging as a critical blood-based neurodegenerative biomarker;
  • The challenges with measuring low-abundant biomarkers;
  • How SMC®️ technology was used to develop assays for easy and sensitive detection of low-abundant blood-based biomarkers.

For Research Use Only. Not For Use In Diagnostic Procedures.

Webinar brought to you by:


This webinar is sponsored by Merck KGaA, Darmstadt, Germany. MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

Enter your details to view this webinar on-demand

[Merck] Webinar 24-May-22 Developing a Novel Ultrasensitive

  • Do you have a need for high sensitivity measurement of neurodegenerative biomarkers as part of your research? (Select one)
  • By registering you agree that Merck KGaA, Darmstadt, Germany and Bitesize Bio may contact you in the future with follow up material about this webinar and other related information. You can unsubscribe with one click at any time.
  • This field is for validation purposes and should be left unchanged.

All Bitesize Bio emails contain an unsubscribe link.
You can review our privacy policy, cookie policy and terms and conditions online.

Share this to your network:
LinkedIn
Scroll To Top